Evidence map›Paper›PMID 38945933›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Recurrent Cerebral Hemorrhaging with Platelet Dysfunction Accompanied by Anti-glycoprotein VI Autoantibodies in a Patient with TAFRO Syndrome.

Akira Yamamoto, Hisakazu Nishimori, Toshiaki Shirai, Katsuhiro Takano, Aya Komura, Yui Kambara, Takuya Fukumi, Tomohiro Urata, Noboru Asada, Daisuke Ennishi and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akira YamamotoDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Hisakazu NishimoriDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Toshiaki ShiraiDepartment of Clinical and Laboratory Medicine, University of Yamanashi, Japan.
Katsuhiro TakanoDivision of Transfusion Medicine and Cell Therapy, University of Yamanashi, Japan.
Aya KomuraDepartment of Hematology, Okayama City Hospital, Japan.
Yui KambaraDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Takuya FukumiDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Tomohiro UrataDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Noboru AsadaDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Daisuke EnnishiDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Keiko FujiiDivision of Clinical Laboratory, Okayama University Hospital, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Japan.
Kenji NiiyaJunpukai Health Maintenance Center, Japan.
Katsue Suzuki-InoueDepartment of Clinical and Laboratory Medicine, University of Yamanashi, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombocytopenia, anasarca, fever, renal dysfunction, and organomegaly (TAFRO) syndrome is an inflammatory disorder with an unclear pathogenesis. We herein report a case of TAFRO syndrome in remission in a patient who experienced recurrent intracranial bleeding despite a normal platelet count and coagulation system. A further investigation suggested the presence of anti-glycoprotein VI (GPVI) autoantibodies in the plasma, which induced platelet dysfunction and bleeding tendency. No new bleeding or relapse of TAFRO syndrome occurred after immunosuppressive therapy was initiated. These findings may help elucidate the autoimmune pathogenesis of TAFRO syndrome.

Indexed as

AutoantibodiesRecurrenceBlood Platelet DisordersCerebral HemorrhageFemaleFeverHumansMaleMiddle AgedPlatelet Membrane GlycoproteinsSyndromeThrombocytopeniaAutoantibodiesPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIanti-glycoprotein VI (GPVI) autoantibodyGPVI deficiencyplatelet dysfunctionrecurrent cerebral hemorrhagingTAFRO syndrome

Identifiers

PMID38945933
PMCPMC11272510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.